n-(2-hydroxypropyl)methacrylamide has been researched along with Body Weight in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benayoun, L; Kopeček, J; Kopečková, P; Pan, H; Satchi-Fainaro, R; Segal, E; Shaked, Y | 1 |
| Bellini, O; Duncan, R; Grandi, M; Hopewell, JW; Seymour, LW; Simmonds, RH; Spreafico, F; Strohalm, J; Ulbrich, K; Yeung, TK | 1 |
| Duncan, R; Hume, IC; Kopecek, J; Kopecková, P; Lloyd, JB; Strohalm, J | 1 |
3 other study(ies) available for n-(2-hydroxypropyl)methacrylamide and Body Weight
| Article | Year |
|---|---|
Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Body Weight; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cyclohexanes; Humans; Male; Materials Testing; Mice; Mice, Inbred BALB C; Molecular Structure; O-(Chloroacetylcarbamoyl)fumagillol; Osteosarcoma; Polymers; Sesquiterpenes; Tissue Distribution | 2011 |
Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
Topics: Acrylamides; Animals; Body Weight; Doxorubicin; Drug Combinations; Drug Evaluation, Preclinical; Heart; Heart Failure; Heart Rate; Male; Rats; Rats, Inbred Strains | 1991 |
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.
Topics: Acrylamides; Animals; Body Weight; Daunorubicin; Drug Carriers; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Time Factors; Tissue Distribution | 1988 |